TG Therapeutics Announces $100M Share Buyback Plan
PorAinvest
jueves, 4 de septiembre de 2025, 1:52 am ET1 min de lectura
TGTX--
The new program, authorized by the company's Board of Directors, will allow TG Therapeutics to buy back shares through open-market purchases and other transactions, in accordance with applicable securities laws and subject to market conditions. This initiative follows the successful completion of the company's previously authorized $100 million share repurchase program, which was completed in August 2025.
Under the completed program, TG Therapeutics repurchased approximately 3.5 million shares of its common stock at an average price of $28.55 per share. The new program aims to continue this trend by acquiring up to an additional $100 million of TG Therapeutics' common stock.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, "We are pleased to announce the completion of our previously authorized $100 million share repurchase program. In the month of August, we were able to repurchase approximately $78 million of TG stock at what we believe were highly attractive prices. In addition, our Board of Directors has authorized a new $100 million repurchase program, underscoring our continued commitment to delivering value to shareholders and reflecting our conviction that current market prices do not adequately reflect the multibillion-dollar potential of BRIUMVI or the long-term growth prospects of TG Therapeutics."
The share buyback program is a strategic move that could potentially increase earnings per share and provide investors with a higher return on investment. It also signals the company's confidence in its financial health and future growth prospects.
References:
[1] https://seekingalpha.com/news/4491936-tg-therapeutics-launches-100m-share-buybacks
[2] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase
TG Therapeutics announced a $100M share buyback program, allowing the company to purchase shares through open-market transactions. The program reflects its commitment to generating shareholder value.
New York, Sept. 02, 2025 — TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a new share repurchase program worth up to $100 million. This move reflects the company's commitment to generating shareholder value and underscores its confidence in the current market conditions.The new program, authorized by the company's Board of Directors, will allow TG Therapeutics to buy back shares through open-market purchases and other transactions, in accordance with applicable securities laws and subject to market conditions. This initiative follows the successful completion of the company's previously authorized $100 million share repurchase program, which was completed in August 2025.
Under the completed program, TG Therapeutics repurchased approximately 3.5 million shares of its common stock at an average price of $28.55 per share. The new program aims to continue this trend by acquiring up to an additional $100 million of TG Therapeutics' common stock.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, "We are pleased to announce the completion of our previously authorized $100 million share repurchase program. In the month of August, we were able to repurchase approximately $78 million of TG stock at what we believe were highly attractive prices. In addition, our Board of Directors has authorized a new $100 million repurchase program, underscoring our continued commitment to delivering value to shareholders and reflecting our conviction that current market prices do not adequately reflect the multibillion-dollar potential of BRIUMVI or the long-term growth prospects of TG Therapeutics."
The share buyback program is a strategic move that could potentially increase earnings per share and provide investors with a higher return on investment. It also signals the company's confidence in its financial health and future growth prospects.
References:
[1] https://seekingalpha.com/news/4491936-tg-therapeutics-launches-100m-share-buybacks
[2] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios